|
1
|
Adjei AA: Lung cancer worldwide. J Thorac
Oncol. 14(956)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Adams SJ, Stone E, Baldwin DR,
Vliegenthart R, Lee P and Fintelmann FJ: Lung cancer screening.
Lancet. 401:390–408. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y,
Lin D, Gao Q, Zhou H, Liao W and Yao H: Association of survival and
Immune-related biomarkers with immunotherapy in patients with
non-small cell lung cancer: A Meta-analysis and individual
patient-level analysis. JAMA Netw Open. 2(e196879)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Steven A, Fisher SA and Robinson BW:
Immunotherapy for lung cancer. Respirology. 21:821–833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rupp B, Ball H, Wuchu F, Nagrath D and
Nagrath S: Circulating tumor cells in precision medicine:
Challenges and opportunities. Trends Pharmacol Sci. 43:378–391.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aceto N: Bring along your friends:
Homotypic and heterotypic circulating tumor cell clustering to
accelerate metastasis. Biomed J. 43:18–23. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gires O, Pan M, Schinke H, Canis M and
Baeuerle PA: Expression and function of epithelial cell adhesion
molecule EpCAM: Where are we after 40 years? Cancer Metastasis Rev.
39:969–987. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Krebs MG, Hou JM, Sloane R, Lancashire L,
Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, et al:
Analysis of circulating tumor cells in patients with non-small cell
lung cancer using epithelial marker-dependent and -independent
approaches. J Thorac Oncol. 7:306–315. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lin D, Shen L, Luo M, Zhang K, Li J, Yang
Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor
cells: Biology and clinical significance. Signal Transduct Target
Ther. 6(404)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bae SY, Kamalanathan KJ, Galeano-Garces C,
Konety BR, Antonarakis ES, Parthasarathy J, Hong J and Drake JM:
Dissemination of circulating tumor cells in breast and prostate
cancer: Implications for early detection. Endocrinology.
165(bqae022)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mitra A, Mishra L and Li SL: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Joosse SA, Gorges TM and Pantel K:
Biology, detection, and clinical implications of circulating tumor
cells. Embo Mol Med. 7:1–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang X, Wei L, Li J, Zheng J, Zhang S and
Zhou J: Epithelial-mesenchymal transition phenotype of circulating
tumor cells is associated with distant metastasis in patients with
NSCLC. Mol Med Rep. 19:601–608. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhang Y, Men Y, Wang J, Xing P, Zhao J, Li
J, Xu D, Hui Z and Cui W: Epithelial circulating tumor cells with a
heterogeneous phenotype are associated with metastasis in NSCLC. J
Cancer Res Clin Oncol. 148:1137–1146. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pantazaka E, Vardas V, Roumeliotou A,
Kakavogiannis S and Kallergi G: Clinical relevance of mesenchymal-
and stem-associated phenotypes in circulating tumor cells isolated
from lung cancer patients. Cancers (Basel). 13(2158)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bie F, Tian H, Sun N, Zang R, Zhang M,
Song P, Liu L, Peng Y, Bai G, Zhou B and Gao S: Research progress
of Anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive
biomarkers in NSCLC. Front Oncol. 12(769124)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hu CB, Huang C, Wang J, Hong Y, Fan DD,
Chen Y, Lin AF, Xiang LX and Shao JZ: PD-L1/BTLA checkpoint axis
exploited for bacterial immune escape by restraining CD8+ T
Cell-initiated adaptive immunity in Zebrafish. J Immunol.
211:816–835. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Juneja VR, McGuire KA, Manguso RT, LaFleur
MW, Collins N, Haining WN, Freeman GJ and Sharpe AH: PD-L1 on tumor
cells is sufficient for immune evasion in immunogenic tumors and
inhibits CD8 T cell cytotoxicity. J Exp Med. 214:895–904.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Brody R, Zhang Y, Ballas M, Siddiqui MK,
Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in
advanced NSCLC: Insights into risk stratification and treatment
selection from a systematic literature review. Lung Cancer.
112:200–215. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Barclay J, Creswell J and León J: Cancer
immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol.
71:393–399. 2018.PubMed/NCBI
|
|
22
|
Ligero M, Serna G, El Nahhas OSM, Sansano
I, Mauchanski S, Viaplana C, Calderaro J, Toledo RA, Dienstmann R,
Vanguri RS, et al: Weakly supervised deep learning predicts
immunotherapy response in solid tumors based on PD-L1 expression.
Cancer Res Commun. 4:92–102. 2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hou F, Qi C, Lu Y, Li F and Hao Z: Cell HE
staining smears and paired cell paraffin sections in detection of
epithelial growth factor receptor gene of pleural fluid specimens.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 47:35–44. 2022.PubMed/NCBI View Article : Google Scholar : (In English,
Chinese).
|
|
24
|
Davies CR, Guo T, Burke E, Stankiewicz E,
Xu L, Mao X, Scandura G, Rajan P, Tipples K, Alifrangis C, et al:
The potential of using circulating tumour cells and their gene
expression to predict docetaxel response in metastatic prostate
cancer. Front Oncol. 12(1060864)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Castro-Giner F and Aceto N: Tracking
cancer progression: From circulating tumor cells to metastasis.
Genome Med. 12(31)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang H, Yuan F, Qi Y, Liu B and Chen Q:
Circulating tumor cells for Glioma. Front Oncol.
11(607150)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liang DH, Hall C and Lucci A: Circulating
tumor cells in breast cancer. Recent Results Cancer Res.
215:127–145. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pantel K: Circulating tumor cells in head
and neck carcinomas. Clin Chem. 65:1193–1195. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Massari F, Di Nunno V, Comito F, Cubelli
M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R and
Ardizzoni A: Circulating tumor cells in genitourinary tumors. Ther
Adv Urol. 10:65–77. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Castello A, Carbone FG, Rossi S, Monterisi
S, Federico D, Toschi L and Lopci E: Circulating tumor cells and
metabolic parameters in NSCLC patients treated with checkpoint
inhibitors. Cancers (Basel). 12(487)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen M, Xu R, Wu L and Chen X:
Relationship between circulating tumor cells undergoing EMT and
short-term efficacy following interventional treatment in patients
with hepatocellular carcinoma. J Interv Med. 3:146–150.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Thunnissen E, de Langen AJ and Smit EF:
PD-L1 IHC in NSCLC with a global and methodological perspective.
Lung Cancer. 113:102–105. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni
P, Qin A, Zhao L, Azizi E, Lawrence TS, Ramnath N, et al: PD-L1
expression in circulating tumor cells increases during
Radio(chemo)therapy and indicates poor prognosis in Non-small cell
lung cancer. Sci Rep. 9(566)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cheng Y, Wang T, Lv X, Li R, Yuan L, Shen
J, Li Y, Yan T, Liu B and Wang L: Detection of PD-L1 expression and
its clinical significance in circulating tumor cells from patients
with Non-small-cell lung cancer. Cancer Manag Res. 12:2069–2078.
2020.PubMed/NCBI View Article : Google Scholar
|
